<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272960</url>
  </required_header>
  <id_info>
    <org_study_id>SFP4-13</org_study_id>
    <nct_id>NCT01272960</nct_id>
  </id_info>
  <brief_title>Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial</brief_title>
  <acronym>MISTIC</acronym>
  <official_title>Randomized, Open-label, Controlled Trial of Immediate Postpartum Versus Interval Insertion of Mirena to Increase the Usage at 6 Months After Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to determine the timing of LNG-IUS insertion that results in a greater proportion of
      women using the LNG-IUS at 6-months post-partum, we will perform a randomized control trial
      of interval versus immediate post-placenta insertion. Women will be enrolled at 36-weeks
      gestation and greater. At the time of vaginal delivery, women will be randomized to receive
      either immediate post-placenta insertion of the LNG-IUS or routine insertion at 4-8 weeks
      post-partum. All patients will return at 4-6 weeks post-insertion and 6 months post-partum to
      confirm correct position of the LNG-IUS. The primary outcome of this sub-study is the number
      of LNG-IUS in the correct position at 6-months. Secondary outcomes include assessing the
      safety of post-placental LNG-IUS insertion and difference in acceptability and symptoms
      experienced by participants. This is a sub-study of the Contraceptive Choice Project, a
      prospective cohort study that aims to improve the use of long-acting contraception by
      removing financial barriers which has already enrolled over 5,000 patients. Association of
      this study with CHOICE offers unique advantages including infrastructure to support subject
      recruitment, retention and completion of follow-up as well as covering the cost of LNG-IUS
      devices.

      We hypothesize that, despite higher expulsion rates, women randomized to receive the LNG-IUS
      immediately after placenta delivery will have higher rates of LNG-IUS continuation due to
      poor rates of follow up in the interval insertion group. This is likely to be particularly
      noticeable in our patient population, which is largely uninsured with poor access to
      healthcare. Further, typical symptoms of LNG-IUS insertion include bleeding and cramping,
      which may be disguised by the post-partum period. Published reports of immediate
      post-placenta insertion focus on expulsion rates and do not report on symptoms and
      satisfaction rates.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mirena in Place</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of women in each arm with Mirena in place at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mirena Expulsion</measure>
    <time_frame>6 weeks</time_frame>
    <description>The percentage of patients with post-placental placement of Mirena who experience an expulsion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine Perforation</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of patients in each arm who experience a uterine perforation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine Infection</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of patients in each arm who experience an intrauterine infection (endometritis, pelvic inflammatory disease)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Postpartum Period</condition>
  <arm_group>
    <arm_group_label>Interval Insertion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Placental Mirena Insertion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive Mirena insertion within 10 minutes of delivery of placenta</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Post-Placenta Mirena Insertion</intervention_name>
    <description>Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta</description>
    <arm_group_label>Post-Placental Mirena Insertion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interval Insertion</intervention_name>
    <description>Insertion of Mirena 4-8 weeks post partum after vaginal delivery</description>
    <arm_group_label>Interval Insertion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  14-45 years

          -  Vaginal Delivery at Barnes-Jewish Hospital

          -  Sexually active with male partner

          -  No tubal ligation/hysterectomy

          -  Not currently using contraception

          -  Desire reversible contraception

          -  Reside in St. Louis City/County

          -  Requests Mirena(R) intrauterine device for contraception

        Exclusion Criteria:

          -  Allergy to Mirena(R) system

          -  Cesarean delivery

          -  Cervical cancer, breast cancer

          -  Active liver disease

          -  Untreated cervicitis

          -  Uterine anomaly/fibroids preventing Mirena(R) placement

          -  Delivery &lt;36 weeks

          -  Chorioamnionitis

          -  Prolonged rupture of membranes (&gt;18 hours)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorie M Harper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006 Jun;38(2):90-6.</citation>
    <PMID>16772190</PMID>
  </reference>
  <reference>
    <citation>Gillett PG, Lee NH, Yuzpe AA, Cerskus I. A comparison of the efficacy and acceptability of the Copper-7 intrauterine device following immediate or delayed insertion after first-trimester therapeutic abortion. Fertil Steril. 1980 Aug;34(2):121-4.</citation>
    <PMID>7409230</PMID>
  </reference>
  <reference>
    <citation>Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril. 1994 Jan;61(1):70-7.</citation>
    <PMID>8293847</PMID>
  </reference>
  <reference>
    <citation>Comparative multicentre trial of three IUDs inserted immediately following delivery of the placenta. Contraception. 1980 Jul;22(1):9-18.</citation>
    <PMID>7418410</PMID>
  </reference>
  <reference>
    <citation>Thiery M, Van Kets H, Van der Pas H. Immediate post-placental IUD insertion: the expulsion problem. Contraception. 1985 Apr;31(4):331-49.</citation>
    <PMID>4006467</PMID>
  </reference>
  <reference>
    <citation>Morrison C, Waszak C, Katz K, Diabaté F, Mate EM. Clinical outcomes of two early postpartum IUD insertion programs in Africa. Contraception. 1996 Jan;53(1):17-21.</citation>
    <PMID>8631184</PMID>
  </reference>
  <reference>
    <citation>Xu JX, Reusché C, Burdan A. Immediate postplacental insertion of the intrauterine device: a review of Chinese and the world's experiences. Adv Contracept. 1994 Mar;10(1):71-82. Review.</citation>
    <PMID>8030457</PMID>
  </reference>
  <reference>
    <citation>Zhou SW, Chi IC. Immediate postpartum IUD insertions in a Chinese hospital--a two year follow-up. Int J Gynaecol Obstet. 1991 Jun;35(2):157-64.</citation>
    <PMID>1680090</PMID>
  </reference>
  <reference>
    <citation>Eroğlu K, Akkuzu G, Vural G, Dilbaz B, Akin A, Taşkin L, Haberal A. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception. 2006 Nov;74(5):376-81. Epub 2006 Sep 15.</citation>
    <PMID>17046378</PMID>
  </reference>
  <reference>
    <citation>Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2010 Nov;116(5):1079-87. doi: 10.1097/AOG.0b013e3181f73fac.</citation>
    <PMID>20966692</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <results_first_submitted>May 16, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2017</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Postnatal care</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>53 participants were enrolled but only 29 randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Interval Insertion</title>
          <description>Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
Post-Placenta Mirena Insertion: Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta</description>
        </group>
        <group group_id="P2">
          <title>Post-Placental Mirena Insertion</title>
          <description>Will receive Mirena insertion within 10 minutes of delivery of placenta
Post-Placenta Mirena Insertion: Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interval Insertion</title>
          <description>14 subjects received Mirena at 4-8 weeks post-partum after vaginal delivery.</description>
        </group>
        <group group_id="B2">
          <title>Post-Placental Mirena Insertion</title>
          <description>15 received Mirena insertion within 10 minutes of delivery of placenta</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="4.6"/>
                    <measurement group_id="B2" value="26.9" spread="4.2"/>
                    <measurement group_id="B3" value="26.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of pregnancies at viable gestational age</title>
          <units>Pregnancies</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mirena in Place</title>
        <description>Proportion of women in each arm with Mirena in place at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post Placental Mirena Insertion</title>
          </group>
          <group group_id="O2">
            <title>Interval Insertion</title>
          </group>
        </group_list>
        <measure>
          <title>Mirena in Place</title>
          <description>Proportion of women in each arm with Mirena in place at 6 months</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mirena Expulsion</title>
        <description>The percentage of patients with post-placental placement of Mirena who experience an expulsion</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interval Insertion</title>
            <description>Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
Post-Placenta Mirena Insertion: Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta</description>
          </group>
          <group group_id="O2">
            <title>Post-Placental Mirena Insertion</title>
            <description>Will receive Mirena insertion within 10 minutes of delivery of placenta
Post-Placenta Mirena Insertion: Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta</description>
          </group>
        </group_list>
        <measure>
          <title>Mirena Expulsion</title>
          <description>The percentage of patients with post-placental placement of Mirena who experience an expulsion</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uterine Perforation</title>
        <description>The proportion of patients in each arm who experience a uterine perforation</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interval Insertion</title>
            <description>Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
Interval Insertion: Insertion of Mirena 4-8 weeks post partum after vaginal delivery</description>
          </group>
          <group group_id="O2">
            <title>Post-Placental Mirena Insertion</title>
            <description>Will receive Mirena insertion within 10 minutes of delivery of placenta
Post-Placenta Mirena Insertion: Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta</description>
          </group>
        </group_list>
        <measure>
          <title>Uterine Perforation</title>
          <description>The proportion of patients in each arm who experience a uterine perforation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intrauterine Infection</title>
        <description>The proportion of patients in each arm who experience an intrauterine infection (endometritis, pelvic inflammatory disease)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interval Insertion</title>
            <description>Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
Post-Placenta Mirena Insertion: Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta</description>
          </group>
          <group group_id="O2">
            <title>Post-Placental Mirena Insertion</title>
            <description>Will receive Mirena insertion within 10 minutes of delivery of placenta
Post-Placenta Mirena Insertion: Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta</description>
          </group>
        </group_list>
        <measure>
          <title>Intrauterine Infection</title>
          <description>The proportion of patients in each arm who experience an intrauterine infection (endometritis, pelvic inflammatory disease)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Interval Insertion</title>
        </group>
        <group group_id="E2">
          <title>Post Placental Mirena Insertion</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>One LNG-IUS was removed in the immediate insertion group and not replaced due to a systemic Group B streptococcus infection diagnosed within 6-weeks post-partum.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Inability to recruit and randomize our target sample size, to detect rare adverse events that may be associated with immediate insertion, women randomized to immediate insertion were more likely to return for their 6-month string check visit.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Lorie Harper</name_or_title>
      <organization>University of Alabama School of Medicine</organization>
      <phone>205-975-0515</phone>
      <email>lmharper@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

